Logo

Neumann Diagnostics Automated Cervical Cancer Test

Feb 04, 2016

Neumann Diagnostics has launched its Confidence molecular test portfolio for cervical cancer screening. The test portfolio consists of a human papillomavirus test and an epigenetic biomarker and was evaluated in a multicentre clinical trial involving over 7,000 cervical samples collected from over 6,000 women. In HPV-positive women, aged 25 years or older, the test's sensitivity for severe cervical dysplasia or worse condition at baseline was about 92 percent and its specificity in the same group was about 74 percent. The clinical trial showed that Confidence tests found severe cases up to 12 months earlier than a Pap smear, according to the firm.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.